Hyperleucocytosis and Leucostasis in Acute Myeloid Leukaemia: A Challenging Clinical Situation
Abstract
Hyperleucocytosis is defined as a white cell count (WBC) >50 x 109/L or commonly 100 x 109/L in a patient with leukaemia. Hyperleucocytosis with leucostasis is most often seen in patients with Acute Myeloid leukaemia (AML). AML with hyperleucocytosis is thought to have a poor prognosis because of a higher risk of early death due to complications such as disseminated intravascular coagulation (DIC), tumour lysis syndrome (TLS), and leucostasis, as well as a higher likelihood of long-term relapse. Leucostasis is considered a medical emergency since it has the potential to cause ischemia in vital organs with high mortality requiring immediate intervention. The molecular mechanisms that cause hyperleucocytosis are not well known. The molecular mechanisms behind hyperleucocytosis remain poorly understood.
Full text article
References
Siegel RL, Miller KD, Jemal A: Cancer statistics, 2017. CA Cancer J Clin. 2017, 67:7-30.
Dutcher JP, Schiffer CA, Wiernik PH. Hyperleucocytosis in adult acute nonlymphocytic leukaemia: impact on remission rate and duration, and survival. J Clin Oncol. 1987 Sep; 5(9):1364-72. doi: 10.1200/JCO.1987.5.9.1364. PMID: 3625254.
Vaughan WP, Kimball AW, Karp JE, Dragon LH, Burke PJ. Factors affecting survival of patients with acute myelocytic leukaemia presenting with high WBC counts. Cancer Treat Rep. 1981 Nov-Dec; 65(11-12):1007-13. PMID: 6945910.
Cuttner J, Holland JF, Norton L, Ambinder E, Button G, Meyer RJ. Therapeutic leukapheresis for hyperleucocytosis in acute myelocytic leukaemia. Med Pediatr Oncol. 1983;11(2):76-8. doi: 10.1002/mpo.2950110203. PMID: 6572782.
Ventura GJ, Hester JP, Smith TL, Keating MJ. Acute myeloblastic leukaemia with hyperleucocytosis: risk factors for early mortality in induction. Am J Hematol. 1988 Jan;27(1):34-7. doi: 10.1002/ajh.2830270109. PMID: 3162645.
Hug V, Keating M, McCredie K, Hester J, Bodey GP, Freireich EJ. Clinical course and response to treatment of patients with acute myelogenous leukaemia presenting with a high leukocyte count. Cancer. 1983 Sep 1;52(5):773-9. doi: 10.1002/1097-0142(19830901)52:5<773::aid-cncr2820520503>3.0.co;2-x. PMID: 6575857.
Porcu P, Danielson CF, Orazi A, Heerema NA, Gabig TG, McCarthy LJ. Therapeutic leukapheresis in hyperleucocytic leukaemias: lack of correlation between degree of cytoreduction and early mortality rate. Br J Haematol. 1997 Aug;98(2):433-6. doi: 10.1046/j.1365-2141.1997.1943011.x. PMID: 9266944.
Creutzig U, Ritter J, Budde M, Sutor A, Schellong G. Early deaths due to haemorrhage and leucostasis in childhood acute myelogenous leukaemia. Associations with hyperleucocytosis and acute monocytic leukaemia. Cancer. 1987 Dec 15;60(12):3071-3079. doi: 10.1002/1097-0142(19871215)60:12<3071::aid-cncr2820601235>3.0.co;2-y. PMID: 3479232.
Bunin NJ, Pui CH. Differing complications of hyperleucocytosis in children with acute lymphoblastic or acute nonlymphoblastic leukaemia. J Clin Oncol. 1985 Dec;3(12):1590-5. doi: 10.1200/JCO.1985.3.12.1590. PMID: 3864942.10. Bunin NJ, Pui CH.
Pastore F, Pastore A, Wittmann G, Hiddemann W, Spiekermann K (2014) The Role of Therapeutic Leukapheresis in Hyperleukocytotic AML. PLoS ONE 9(4): e95062. doi:10.1371/journal.pone.0095062.
Byrd JC, Mrózek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC, Pettenati MJ, Patil SR, Rao KW, Watson MS, Koduru PR, Moore JO, Stone RM, Mayer RJ, Feldman EJ, Davey FR, Schiffer CA, Larson RA, Bloomfield CD; Cancer and Leukaemia Group B (CALGB 8461). Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukaemia: results from Cancer and Leukaemia Group B (CALGB 8461). Blood. 2002 Dec 15;100(13):4325-36. doi: 10.1182/blood-2002-03-0772. Epub 2002 Aug 1. PMID: 12393746.
Rollig C, Ehninger G. How I treat hyperleucocytosis in acute myeloid leukaemia. Blood. 2015;125:3246–3252.
Ali A, Mirrakhimov A, Abboud C, Cashen A. Leucostasis in adult acute hyperleukocytic leukaemia: a clinician’s digest. Hematol Oncol. 2016;34(2):69–78.
Stucki A, Rivier AS, Gikic M, Monai N, Schapira M, Spertini O. Endothelial cell activation by myeloblasts: molecular mechanisms of leukostasis and Leukaemic cell dissemination. Blood. 2001 Apr 1;97(7):2121-9.
Azoulay É, Fieux F, Moreau D, Thiery G, Rousselot P, Parrot A, Le Gall JR, Dombret H, Schlemmer B. Acute monocytic leukemia presenting as acute respiratory failure. American journal of respiratory and critical care medicine. 2003 May 15;167(10):1329-33.
Schiffer CA, Wiernik PH. Functional evaluation of circulating Leukaemic cells in acute non-lymphocytic leukaemia. Leuk Res 1977; 1:271.
Bewersdorf JP, Zeidan AM. Hyperleukocytosis and leukostasis in acute myeloid leukemia: can a better understanding of the underlying molecular pathophysiology lead to novel treatments?. Cells. 2020 Oct 17;9(10):2310. https://doi.org/10.3390/cells9102310
Macaron W, Sargsyan Z, Short NJ. Hyperleukocytosis and leukostasis in acute and chronic leukemias. Leukemia & Lymphoma. 2022 Jul 3;63(8):1780-91.
Ganzel C, Becker J, Mintz PD, Lazarus HM, Rowe JM. Hyperleucocytosis, leucostasis and leukapheresis: practice management. Blood Rev. 2012;26(3):117–122
Pastore F, Pastore A, Wittmann G, Hiddemann W, Spiekermann K. The role of therapeutic leukapheresis in hyperleukocytotic AML. PLoS One. 2014 Apr 14;9(4):e95062. doi: 10.1371/journal.pone.0095062.
Daver N, Kantarjian H, Marcucci G, Pierce S, Brandt M, Dinardo C, Pemmaraju N, Garcia‐Manero G, O'Brien S, Ferrajoli A, Verstovsek S. Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis. British journal of haematology. 2015 Mar;168(5):646-53.
Thiede C, Steudel C, Mohr B, Schaich M, Schäkel U, Platzbecker U, Wermke M, Bornhäuser M, Ritter M, Neubauer A, Ehninger G. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood. 2002 Jun 15;99(12):4326-35. doi: 10.1182/blood.V99.12.4326.
Schoch C, Schnittger S, Klaus M, Kern W, Hiddemann W, Haferlach T. AML with 11q23/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases. Blood. 2003 Oct 1;102(7):2395-402. doi: 10.1182/blood-2003-02-0434
Y Kaneko, N Maseki, N Takasaki, M Sakurai, Y Hayashi, S Nakazawa, T Mori, M Sakurai, T Takeda, T Shikano; Clinical and hematologic characteristics in acute leukemia with 11q23 translocations. Blood 1986; 67 (2): 484–491. doi: https://doi.org/10.1182/blood.V67.2.484.484
Fröhling S, Schlenk RF, Breitruck J, Benner A, Kreitmeier S, Tobis K, Döhner H, Döhner K. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood. 2002 Dec 15;100(13):4372-80.
Bewersdorf JP, Zeidan AM. Hyperleukocytosis and leukostasis in acute myeloid leukemia: can a better understanding of the underlying molecular pathophysiology lead to novel treatments?. Cells. 2020 Oct 17;9(10):2310.
Tien FM, Hou HA, Tsai CH, Tang JL, Chen CY, Kuo YY, Li CC, Lin CT, Yao M, Huang SY, Ko BS, Hsu SC, Wu SJ, Tsay W, Tseng MH, Liu MC, Liu CW, Lin LI, Chou WC, Tien HF. Hyperleucocytosis is associated with distinct genetic alterations and is an independent poor-risk factor in de novo acute myeloid leukaemia patients. Eur J Haematol. 2018 Jul;101(1):86-94. doi: 10.1111/ejh.13073. Epub 2018 May 22. PMID: 29624746.
Porcu P, Farag S, Marcucci G, Cataland SR, Kennedy MS, Bissell M. Leukocytoreduction for acute leukaemia. Ther Apher. 2002 Feb;6(1):15-23. doi: 10.1046/j.1526-0968.2002.00402.x. PMID: 11886572.
Shallis RM, Stahl M, Bewersdorf JP, Hendrickson JE, Zeidan AM. Leukocytapheresis for patients with acute myeloid leukemia presenting with hyperleukocytosis and leukostasis: a contemporary appraisal of outcomes and benefits. Expert Review of Hematology. 2020 May 3;13(5):489-99. doi: 10.1080/17474086.2020.1751609.
Schwartz JH, Cannellos GP. Hydroxyurea in the management of the hematologic complications of chronic granulocytic leukaemia. Blood 1975; 46(1): 11–16.
Grund FM, Armitage JO, Burns P. Hydroxyurea in the prevention of the effects of leucostasis in acute leukaemia. Arch Intern Med 1977; 137(9): 1246–1247.
von Eyben FE, Siddiqui MZ, Spanos G. High-voltage irradiation and hydroxyurea for pulmonary leucostasis in acute myelomonocytic leukaemia. Acta Haematol 1987; 77(3): 180–182.
Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, Ebert BL, Fenaux P, Godley LA, Hasserjian RP, Larson RA. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022 Sep 22;140(12):1345-77.
Hölig K, Moog R. Leukocyte Depletion by Therapeutic Leukocytapheresis in Patients with Leukaemia. Transfus Med Hemother. 2012 Aug;39(4):241-245. doi: 10.1159/000341805. Epub 2012 Jul 26. PMID: 22969693; PMCID: PMC3434324.
Padmanabhan A, Connelly-Smith L, Aqui N, Balogun RA, Klingel R, Meyer E, Pham HP, Schneiderman J, Witt V, Wu Y, Zantek ND, Dunbar NM, Schwartz GEJ. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice - Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue. J Clin Apher. 2019 Jun;34(3):171-354. doi: 10.1002/jca.21705. PMID: 31180581.
Bewersdorf JP, Giri S, Tallman MS, Zeidan AM, Stahyperleucocytosis M. Leukapheresis for the management of hyperleucocytosis in acute myeloid leukaemia-A systematic review and meta-analysis. Transfusion. 2020 Oct;60(10):2360-2369. doi: 10.1111/trf.15994. Epub 2020 Aug 10. PMID: 32776542; PMCID: PMC8631180.
Stahl M, Shallis RM, Wei W, Montesinos P, Lengline E, Neukirchen J, Bhatt VR, Sekeres MA, Fathi AT, Konig H, Luger S. Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short-and long-term clinical outcomes: a large, retrospective, multicenter, international study. Leukemia. 2020 Dec;34(12):3149-60.
Oberoi S, Lehrnbecher T, Phillips B, Hitzler J, Ethier MC, Beyene J, Sung L. Leukapheresis and low-dose chemotherapy do not reduce early mortality in acute myeloid leukemia hyperleukocytosis: a systematic review and meta-analysis. Leukemia research. 2014 Apr 1;38(4):460-8.
Szczepiorkowski ZM, Winters JL, Bandarenko N, et al. Guidelines on the use of therapeutic apheresis in clinical practice—Evidence-based approach from the apheresis applications committee of the American Society for Apheresis. J Clin Apher, 2010; 25:81-177.
Vahdat L, Maslak P, Miller WH Jr, Eardley A, Heller G, Scheinberg DA, Warrell RP Jr. Early mortality and the retinoic acid syndrome in acute promyelocytic leukaemia: impact of leukocytosis, low-dose chemotherapy, PMN/RAR-alpha isoform, and CD13 expression in patients treated with all-trans retinoic acid. Blood. 1994 Dec 1;84(11):3843-9. PMID: 7949141.
Giles FJ, Shen Y, Kantarjian HM, Korbling MJ, O'brien S, Anderlini P, Donato M, Pierce S, Keating MJ, Freireich EJ, Estey E. Leukapheresis reduces early mortality in patients with acute myeloid leukemia with high white cell counts but does not improve long term survival. Leukemia & lymphoma. 2001 Jan 1;42(1-2):67-73.
Chang MC, Chen TY, Tang JL, Lan YJ, Chao TY, Chiu CF, Ho HT. Leukapheresis and cranial irradiation in patients with hyperleukocytic acute myeloid leukemia: no impact on early mortality and intracranial hemorrhage. American journal of hematology. 2007 Nov;82(11):976-80.
Choi MH, Choe YH, Park Y, Nah H, Kim S, Jeong SH, Kim HO. The effect of therapeutic leukapheresis on early complications and outcomes in patients with acute leukemia and hyperleukocytosis: a propensity score‐matched study. Transfusion. 2018 Jan;58(1):208-16.
Nan X, Qin Q, Gentille C, Ensor J, Leveque C, Pingali SR, Phan AT, Rice L, Iyer S. Leukapheresis reduces 4-week mortality in acute myeloid leukemia patients with hyperleukocytosis–a retrospective study from a tertiary center. Leukemia & Lymphoma. 2017 Sep 2;58(9):2110-7.
Wong GC. Hyperleucocytosis in acute myeloid leukaemia patients is associated with high 30-day mortality which is not improved with leukapheresis. Ann Hematol 2015; 94:2067.
Azoulay É, Canet E, Raffoux E, Lengliné E, Lemiale V, Vincent F, de Labarthe A, Seguin A, Boissel N, Dombret H, Schlemmer B. Dexamethasone in patients with acute lung injury from acute monocytic leukaemia. European Respiratory Journal. 2012 Mar 1;39(3):648-53.
Zhao J, Bewersdorf JP, Jaszczur S, Kowalski A, Perreault S, Schiffer M, Gore S, Podoltsev N, Prebet T, Shallis R, Zeidan AM. High dose cyclophosphamide for cytoreduction in patients with acute myeloid leukaemia with hyperleucocytosis or leucostasis. Leuk Lymphoma. 2021 May;62(5):1195-1202. doi: 10.1080/10428194.2020.1856835. Epub 2020 Dec 16. PMID: 33325761.
Authors
Copyright (c) 2024 Mujahida Rahman, Munim Ahmed, Md. Kamrul Hasan
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open access article published under the Creative Commons Attribution 4.0 International License, which permits its free use, distribution, and reproduction in any medium or format, even used for commercial purposes, provided the original work is properly cited.